Polycan in Combination With Glucosamine for Treatment of Knee Osteoarthritis
NCT ID: NCT03717714
Last Updated: 2018-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2017-04-01
2018-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Tolerability of Proteoglycan F in the Treatment of Knee Osteoarthritis
NCT04998825
Effect of Prebiotics on Function and Pain in Patients with Osteoarthritis and Obesity
NCT04172688
The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee
NCT02333084
Efficacy of Non-animal Chondroitin Sulphate for Overweight Subjects With Knee Ostoarthritis.
NCT03731793
Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis
NCT07189585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glucosamine 1500mg
Glucosamine 1500 mg per day for 12 weeks
Glucosamine 1500 mg
Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Polycan & Glucosamine 750mg
Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
Polycan 50mg + Glucosamine 750 mg
Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
Polycan & Glucosamine 1500mg
Polycan 50 mg + Glucosamine 1500 mg per day
Polycan 50mg + Glucosamine 1500 mg
Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucosamine 1500 mg
Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Polycan 50mg + Glucosamine 750 mg
Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
Polycan 50mg + Glucosamine 1500 mg
Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* OA ranging from grade 1 to grade 3 by Kellgren and Lawrence system
* Agree to participate into the study
Exclusion Criteria
* Allergic or contradicted with oral NSAIDs (Meloxicam)
* Pregnant and breastfeeding women.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vietstar Biomedical Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
198 Hospital
Hanoi, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Polycan-VN01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.